Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132041 · ClinicalTrials.gov registry record · NA
Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
A NA study, sponsored by American College of Radiology Imaging Network.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT00132041 is a NA study that has completed, run by American College of Radiology Imaging Network. The registered enrollment target is 51 participants.
The verdict
NCT00132041, a NA study, has completed, sponsored by American College of Radiology Imaging Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. CT-, MRI-, or ultrasound-guided radiofrequency ablation may be an effective treatment for liver cancer and cirrhosis. PURPOSE: This phase II trial is studying how well radiofrequency ablation works in treating patients with liver cancer and cirrhosis.
Interventions
- DEVICE radiofrequency ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132041
The ClinicalTrials.gov registry entry for NCT00132041 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American College of Radiology Imaging Network, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which radiofrequency ablation is the first listed.
NCT00132041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132041 about?
NCT00132041 is a clinical study titled "Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis". RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. CT-, MRI-, or ultrasound-guided radiofrequency ablation may be an effective treatment for liver cancer and cirrhosis. PURPOSE: This phase II trial is studying how well radiofrequency ablation works in tr...
What is the current status of trial NCT00132041?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2005-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00132041?
The interventions under investigation include: radiofrequency ablation (DEVICE).
Who is sponsoring clinical trial NCT00132041?
This trial is sponsored by American College of Radiology Imaging Network, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.